Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its development partner Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.
Histogenics notes that the Japanese market for cartilage repair is estimated at >200,000 procedures annually and growing, due to favorable demographic trends and national healthcare reforms related to regenerative therapies.
Histogenics will make milestone payments to Purpose upon conditional approval of NeoCart in Japan, as well as commercial milestones and a low-single-digit royalty on Japanese sales of NeoCart, upon full approval in Japan.
Histogenics has passed 50% enrollment in a U.S. Phase III trial to investigate NeoCart vs. microfracture as a first-line approach for the treatment of full thickness adult knee cartilage defects.
Sources: Histogenics Corporation, ORTHOWORLD Inc.
Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its development partner Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.
Histogenics notes that the Japanese market for cartilage repair is estimated at >200,000 procedures...
Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its development partner Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.
Histogenics notes that the Japanese market for cartilage repair is estimated at >200,000 procedures annually and growing, due to favorable demographic trends and national healthcare reforms related to regenerative therapies.
Histogenics will make milestone payments to Purpose upon conditional approval of NeoCart in Japan, as well as commercial milestones and a low-single-digit royalty on Japanese sales of NeoCart, upon full approval in Japan.
Histogenics has passed 50% enrollment in a U.S. Phase III trial to investigate NeoCart vs. microfracture as a first-line approach for the treatment of full thickness adult knee cartilage defects.
Sources: Histogenics Corporation, ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.